Open Access Open Access  Restricted Access Subscription or Fee Access

Treatment for kratom abuse in a contingency-management-based MAT setting: A case series

Seth Kalin, MD, Salaahuddin Dakhlalla, MD, Saurabh Bhardwaj, MD

Abstract


Kratom (Mitragyna speciosa) is a plant extract that exhibits opioid agonistic activity at the μ-opioid receptor. The use of this substance has increased recently due to widespread local availability across the United States (US), primarily at gas stations. Repeated kratom use has been shown to have major adverse effects leading to physiological dependence and addiction similar to other opioids. We used a novel contingency management (CM) program utilizing nonmonetary reinforcers along with medication-assisted treatment (MAT) using buprenorphine in an office-based setting to treat kratom use disorder in two cases. MAT with buprenorphine in a CM-based setting was found to be an effective strategy for treating kratom use disorder.


Keywords


kratom, medication-assisted treatment, opiate use disorder, contingency management

Full Text:

PDF

References


White CM: Pharmacologic and clinical assessment of kratom. Am J Health-Syst Pharm. 2018; 75(5): 261-267.

Hassan Z, Muzaimi M, Navaratnam V, et al.: From kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013; 37: 138-151.

Odonkor, CA, Chang-Chien GC, Amorapanth P: Kratom the new ‘legal high’ on the block?: The case of an emerging opioid receptor agonist with substance abuse potential-case report. Pain Phys. 2017; 20: 195-198.

Stetzel K: The FDA is still trying to ban kratom, a potential solution to the opioid epidemic. Available at https://reason.com/blog/2018/02/12/fda-declares-kratom-an-opioid. Accessed July 15, 2019.

Stolt AC, Schröder H, Neurath H, et al.: Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology. 2014; 231: 13-25.

Drug Enforcement Administration: Kratom (Mitragyna speciose korth). Available at https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf#page=84. Accessed July 10, 2019.

Eggleston W, Stoppacher R, Suen K, et al.: Kratom Use and Toxicities in the United States. Pharmacotherapy. 2019; 39(7): 775–777.

Salsitz E, Wiegand, T: Pharmacotherapy of opioid addiction: “putting a real face on a false demon.” J Med Toxicol. 2016; 12(1): 58-63.

Khazaeli A, Jerry J, Vazirian M: Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018; 12: 493–495.

Buresh M: Treatment of kratom dependence with buprenorphine-naloxone maintenance. J Addict Med. 2018; 12(6): 481-483.

Mattick R, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review). Cochrane Database Syst Rev. 2014; 2: 1-72.

McPherson S, Burduli E, Smith C, et al.: A review of contingency management for treatment of substance-use disorders: Adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Substance Abuse Rehabil. 2018; 9: 43-57.

Carroll K, Weiss R: The role of behavioral interventions in buprenorphine maintenance treatment: A review. Am J Psychiatry. 2017; 174: 738-747.




DOI: https://doi.org/10.5055/jom.2020.0594

Refbacks

  • There are currently no refbacks.